Canadian Journal of Public Health

, Volume 106, Issue 6, pp e454–e456 | Cite as

Persons in correctional facilities in Canada: A key population for hepatitis C prevention and control

  • Fiona G. KouyoumdjianEmail author
  • Kathryn E. McIsaac


About one in nine Canadians who are infected with hepatitis C spend time in a correctional facility each year. With high rates of current injection drug use and needle sharing, this population may account for a large proportion of new infections. Any national strategy to address hepatitis C should include a focus on persons in correctional facilities, and should build on existing evidence regarding primary, secondary and tertiary prevention.

Key Words

Hepatitis C incarcerated prison Canada 

Mots Clés

hépatite C prisonnier prison Canada 


Environ un Canadien sur neuf infecté par l’hépatite C passe du temps dans un établissement de correction chaque année. Avec ses taux élevés d’utilisation actuelle de drogues par injection et de partage d’aiguilles, cette population pourrait représenter une grande proportion des nouveaux cas d’infection. Toute stratégie nationale de lutte contre l’hépatite C devrait mettre l’accent sur les personnes incarcérées et faire fond sur les données probantes existantes concernant la prévention primaire, secondaire et tertiaire.


  1. 1.
    Kwong JC, Ratnasingham S, Campitelli MA, Daneman N, Deeks SL, Manue] DG, et al. The impact of infection on population health: Results of the Ontario burden of infectious diseases study. PLoS One 2012;7:e44103. PMID: 22962601. doi: 10.1371/journal.pone.0044103.CrossRefGoogle Scholar
  2. 2.
    Krajden M, Kuo M, Zagorski B, Alvarez M, Yu A, Krahn M. Health care costs associated with hepatitis C: A longitudinal cohort study. Can J Gastroenterol 2010;24:717–26. PMID: 21165379.CrossRefGoogle Scholar
  3. 3.
    Grebely J, Bilodeau M, Feld JJ, Bruneau J, Fischer B, Raven JF, et al. The Second Canadian Symposium on hepatitis C virus: A call to action. Can J Gastroenterol 2013;27:627–32. PMID: 24199209.CrossRefGoogle Scholar
  4. 4.
    Perrault S. Admissions to Adult Correctional Services in Canada, 2011/2012, 2014._Available at: (Accessed December 14, 2014).Google Scholar
  5. 5.
    Dauvergne M. Adult Correctional Statistics in Canada, 2010/2011, 2012. Available at: (Accessed May 6, 2015).Google Scholar
  6. 6.
    Trubnikov M, Yan P, Archibald C. Estimated prevalence of hepatitis C virus infection in Canada, 2011. Can Commun Dis Rep 2014;40:429–36.CrossRefGoogle Scholar
  7. 7.
    Buxton JA, Rothon D, Durigon M, Lem M, Tu AW, Remple VP, et al. Hepatitis C and HIV prevalence using oral mucosal transudate, and reported drug use and sexual behaviours of youth in custody in British Columbia. Can J Public Health 2009;100:121–24. PMID: 19839288.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Farrell S, Ross J, Ternes M, Kunic D. Prevalence of Injection Drug Use among Male Offenders, 2010. Available at: (Accessed July 29, 2014).Google Scholar
  9. 9.
    Gagnon H, Godin G, Alary M, Lambert G, Lambert LD, Landry S. Prison inmates’ intention to demand that bleach be used for cleaning tattooing and piercing equipment. Can J Public Health 2007;98:297–300. PMID: 17896741.PubMedGoogle Scholar
  10. 10.
    Poulin C, Alary M, Lambert G, Godin G, Landry S, Gagnon H, et al. Prevalence of HIV and hepatitis C virus infections among inmates of Quebec provincial prisons. C MAJ 2007;177:252–56. PMID: 17664448. doi: 10.1503/cmaj.060760.Google Scholar
  11. 11.
    Thompson J, Zakaria D, Grant B. Aboriginal Men: A Summary of the Findings of the 2007 National Inmate Infectious Diseases and Risk-Behaviours Survey, R-237, 2011. Available at: (Accessed June 16, 2014).Google Scholar
  12. 12.
    Strathdee SA, Palepu A, Cornelisse PG, Yip B, O’Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998;280:547–49. PMID: 9707146. doi:10.1001/jama.280.6.547.CrossRefGoogle Scholar
  13. 13.
    Treloar C, Rance J, Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clin Infect Dis 2013; 57(Suppl 2):S51–55. PMID: 23884066. doi: 10.1093/cid/cit263.CrossRefGoogle Scholar
  14. 14.
    Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities. Clin Infect Dis 2005;40(Suppl 5): S339–45. PMID: 15768345. doi: 10.1086/427450.CrossRefGoogle Scholar
  15. 15.
    Lines R, Juergens R, Betteridge G, Stoever H, Laticevschi D, Nelles J. Prison Needle Exchange: Lessons from a Comprehensive Review of International Evidence and Experience, 2006. Available at: (Accessed May 6, 2015).Google Scholar
  16. 16.
    Dolan K, Rutter S, Wodak AD. Prison-based syringe exchange programmes: A review of international research and development. Addiction 2003;98:153–58. PMID: 12534419. doi: 10.1046/j.1360-0443.2003.00309.x.CrossRefGoogle Scholar
  17. 17.
    World Health Organization. Effectiveness of Interventions to Address HIV in Prisons, 2007. Available at: (Accessed May 6, 2015).Google Scholar
  18. 18.
    John-Baptiste A, Yeung MW, Leung V, van der Velde G, Krahn M. Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: A systematic review. Pharmacoeconomics 2012; 30:1015–34. PMID: 23050771. doi: 10.2165/11597660-000000000-00000.CrossRefGoogle Scholar
  19. 19.
    Macarthur GJ, van Velzen E, Palmateer N, Kimber J, Phams A, Hope V et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. Int J Drug Policy 2013;25(1):34–52. PMID: 23973009. doi: 10.1016/j.drugpo.2013.07.001.CrossRefGoogle Scholar
  20. 20.
    Craine N, Whitaker R, Perrett S, Zou L, Hickman M, Lyons M. A stepped wedge cluster randomized control trial of dried blood spot testing to improve the uptake of hepatitis C antibody testing within UK prisons. Eur J Public Health 2015;25:351–57. PMID: 25061233. doi: 10.1093/eurpub/cku096.CrossRefGoogle Scholar
  21. 21.
    Hickman M, McDonald T, Judd A, Nichols T, Hope V, Skidmore S, et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: A cluster randomized controlled trial. J Viral Hepat 2008;15:250–54. PMID: 18086182. doi: 10.1111/j.1365-2893.2007.00937.x.CrossRefGoogle Scholar
  22. 22.
    Farley J, Vasdev S, Fischer B, Haydon E, Rehm J, Farley TA. Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health 2005;95:1737–39. PMID: 16131642. doi: 10.2105/AJPH.2004.056150.CrossRefGoogle Scholar
  23. 23.
    Farley J, Truong A, Nguyen TM, Shum W. Inmate community health re-integration services: A model of care for former inmate population. 63rd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2012 Boston, MA. 2012;56:1034A.Google Scholar
  24. 24.
    Farley J, Truong A, Horvath G, Nguyen T, Shum W. Re-infection of hepatitis C virus infection in HIV/HCV co-infected inmates of correctional institutions, Canada. 11th International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom. 2012;15:87.Google Scholar
  25. 25.
    World Health Organization Europe. Prison Health as Part of Public Health. 2003. Available at: (Accessed May 3, 2015).Google Scholar

Copyright information

© The Canadian Public Health Association 2015

Authors and Affiliations

  1. 1.Centre for Research on Inner City HealthSt. Michael’s HospitalTorontoCanada

Personalised recommendations